A Kelowna biotech company focused on developing psilocybin-based compounds has named a new chief financial officer.
Tryp Therapeutics announced Monday that Jim O’Neill will now be in charge of the company’s finances. O’Neill is taking over for Sid Taubenfeld, who moved from interim CFO to chief operating officer.
“We are excited to welcome Jim to our senior executive team and look forward to leveraging his extensive experience to continue growing our Company,” Tryp CEO Jim Gilligan said in a press release. “Jim’s appointment as CFO demonstrates our continued commitment to establishing Tryp as a leading developer of revolutionary psychedelic drugs for the treatment of unique and under targeted indications.
“We believe his extensive financial expertise and public company experience make him an ideal addition to our team.”
O’Neill has more than 30 years of experience as an international finance executive in both private and public companies. He has worked in Canada, the U.S., the U.K., Turkey and Kenya. He graduated from Wilfrid Laurier University.
“I’m pleased to be joining Tryp Therapeutics at such an exciting and pivotal time in the company’s growth as Tryp makes progress securing patents and advancing the clinical programs to identify potentially revolutionary new method of psychedelic drug treatment,” O’Neill said.
“I look forward to working with the team to capitalize on the market opportunity for TRP-8803 in front of us and to continue driving growth and value for the company.”
All People in Business Stories